Executive Summary

The Continuous Glucose Monitoring Devices Market was valued at 12.7 USD Billion in 2025 and is projected to reach 54.6 USD Billion by 2035, registering a CAGR of 15.7% over the forecast period.

Growth is driven by expanding reimbursement and the newly eligible type 2 diabetic population it created. CMS broadened Medicare Part B coverage of CGM sensors, a Class II device under FDA regulation, in 2024 to type 2 diabetics with documented hypoglycemic episodes, extending market access beyond the insulin-dependent base that had defined standard of care. The EU MDR’s unified pre-market review framework has cut the cost of cross-border device launches, shortening the path from CE marking to a coverage decision in national health systems.

North America held 44.0% of the 2025 market, followed by Asia Pacific at 29.0% and Europe at 21.0%. Sensors led the product axis on consumable pull-through from the installed transmitter base, and Type 2 Diabetes was the largest indication segment.

Reimbursement gaps outside the US and Europe remain the principal constraint; Brazil’s public system offers no routine CGM coverage decision, leaving patients dependent on capillary testing. The market is consolidated among a small set of established sensor manufacturers holding label expansions across multiple indications.

Key Takeaways

• USD 12.69 Billion in 2025, reaching USD 54.55 Billion by 2035 at 15.7% CAGR.
• Sensors led the product axis as the primary recurring-revenue component.
• Real-time CGM sensors are the fastest-expanding product category, displacing intermittent scanning.
• North America held the largest regional share at 44.0% in 2025.
• CMS expanded Medicare Part B CGM coverage to type 2 diabetics in 2024.
• Brazil’s public SUS system offers no routine CGM coverage.

Market Definition and Scope

The Continuous Glucose Monitoring Devices Market covers sensors, transmitters, applicators and reader devices that measure interstitial glucose and transmit trend data to receivers, smartphones or connected insulin pumps. It spans real-time, intermittently scanned and implantable sensor technologies, sold through hospital, retail and direct-to-patient channels for type 1, type 2 and gestational diabetes management alongside broader metabolic monitoring.

Excluded are blood glucose test strips and fingerstick meters, insulin delivery pumps sold independently of sensor integration, and general fitness wearables that do not measure interstitial glucose for clinical decision-making.

Growth Drivers and Restraints

Medicare’s 2024 Part B expansion is pulling type 2 diabetics into the reimbursed base

The Centers for Medicare & Medicaid Services broadened Part B coverage in 2024 to type 2 diabetics with documented hypoglycemic episodes, converting patients who previously paid out of pocket or relied on fingerstick testing into reimbursed CGM users. The change concentrates volume in the Type 2 Diabetes indication segment, the largest by patient count, and routes utilization through endocrinology and primary-care channels that bill Medicare directly. A parallel move in Europe, where a unified pre-market review framework simplifies cross-border CGM launches, has lowered the cost of entering multiple EU states from a single technical file.

Recurring sensor replacement compounds revenue beyond device placement

Real-time and intermittently scanned sensors are worn for a fixed number of days before replacement, so each enrolled patient generates repeat consumable purchases rather than a single sale. Sensors lead the product axis on this basis, ahead of transmitters, applicators and reader hardware, because the wear-and-replace cycle continues for as long as therapy lasts. Layered onto the Part B expansion’s newly enrolled type 2 population, this repeat-purchase pattern is concentrated in North America and underpins the market’s 15.7% CAGR to 2035.

Sensor miniaturization is extending CGM beyond insulin-dependent patients

Implantable and smartphone-compatible sensor formats are widening use beyond Type 1 Diabetes into Type 2, gestational and non-diabetic metabolic monitoring. Gestational diabetes monitoring benefits from a sensor that avoids repeated fingerstick draws during pregnancy, while the metabolic-monitoring category, covering prediabetes and hospital critical-care glucose tracking, extends demand past the diagnosed-diabetes population. Applicators and smartphone-compatible readers, the layer that determines patient comfort and data access, are becoming a purchase differentiator as manufacturers compete for the base opened by Part B.

Public health systems outside the US and Europe exclude CGM from coverage

Brazil’s public health system, the SUS, does not provide CGM or insulin pumps, and private insurance rarely covers them. A 2025 cohort of 92 people with type 1 diabetes at a Brazilian public clinic found none had regular CGM access; all relied on four to five daily fingerstick tests instead. The exclusion is structural: public-system benefit design leaves CGM out entirely, and it caps adoption across Latin America regardless of device availability.

A consolidated manufacturer base slows the price declines needed for broader access

The market’s competitive structure is consolidated among a small number of established sensor manufacturers, which limits the price competition typical of a fragmented field. List prices fall more slowly as a result, delaying affordability-led adoption among self-pay patients outside the reimbursed US, European and Japanese base, particularly across Asia Pacific and Latin America.

Market Trends

Real-time CGM is displacing intermittently scanned systems as the reimbursed default

Real-time CGM (rtCGM) sensors push continuous readings to a receiver or smartphone without a scan step, while intermittently scanned (isCGM) systems require the patient to wave a reader over the sensor to pull a reading. CMS’s 2024 Part B expansion ties reimbursement to type 2 diabetics with documented hypoglycemic episodes, a population for whom continuous alerting carries more clinical value than scan-on-demand data, favoring rtCGM designs through the forecast period.

Smartphone-compatible readers are replacing standalone receivers

Device and reader hardware is splitting into two paths: dedicated standalone receivers and smartphone-compatible readers that display glucose trend data on the patient’s own phone. The unified EU pre-market review framework has lowered the cost of launching a single connected-app platform across member states rather than a country-specific receiver, pushing manufacturers toward the smartphone-linked path for new European launches.

Coverage broadens into type 2 and gestational diabetes while access gaps persist outside high-income markets

Demand is extending from Type 1 Diabetes, CGM’s original indication, into Type 2 and gestational diabetes as reimbursement criteria widen, while a 2025 Brazilian cohort study found that patients at a public-system clinic had no regular CGM access and relied on four to five daily fingerstick tests instead. The split points to a forecast period in which reimbursed markets standardize on CGM and public systems in Latin America continue to depend on capillary testing.

Segment Analysis

By Product

• Sensors (largest) – The disposable component inserted just under the skin that measures glucose in interstitial fluid and relays readings to a transmitter

• Real-Time CGM (rtCGM) Sensors
• Intermittently Scanned CGM (isCGM) Sensors
• Implantable CGM Sensors
• Transmitters – The reusable electronic unit that attaches to the sensor and wirelessly sends glucose data to a receiver, smartphone, or insulin pump

• Reusable Transmitters
• Disposable/Integrated Transmitters

• Applicators – A spring-loaded insertion tool used to place the sensor under the skin quickly and with minimal discomfort to the patient
• Device/Readers – A handheld display unit that receives, stores, and shows glucose readings and trend data transmitted from the sensor system

• Standalone Receivers
• Smartphone-Compatible Readers

By Product

Sensors lead the product axis in 2025, ranking ahead of transmitters, applicators and device readers. They lead because the sensor is the disposable component replaced every seven to fourteen days, so payer billing and pharmacy-benefit design are built around the sensor’s wear cycle rather than around the durable transmitter or reader hardware. That recurring-purchase structure gives sensor revenue a scale no other product category matches, and it ties a patient to one manufacturer’s ecosystem once a sensor form factor is prescribed. Within the category, real-time CGM sensors are growing fastest, gaining ground on intermittently scanned systems as patients move toward continuous, alarm-enabled glucose data rather than periodic scans. The pull is automated insulin delivery: a pump can only dose against a live glucose feed, not a scanned one, and clinicians increasingly favor alarm-triggered hypoglycemia alerts over patient-initiated scanning.

By Indication

Type 2 Diabetes is the leading indication in 2025, ahead of Type 1 Diabetes, gestational diabetes and other metabolic monitoring. It leads on population base: Type 2 patients vastly outnumber Type 1 patients, and payer coverage has broadened beyond insulin-intensive regimens to include Type 2 patients on basal insulin or oral therapy, a group historically monitored by fingerstick alone. Other diabetes and metabolic monitoring, spanning prediabetes and non-diabetic wellness use, is growing fastest. That growth is pulled by CGM’s move outside a formal diabetes diagnosis, as consumer-facing wearables put glycemic trend data in front of prediabetic and metabolically curious users who were never a device candidate under a strict indication label.

By Indication

• Type 1 Diabetes – An autoimmune condition requiring lifelong insulin therapy, where CGM devices track glucose fluctuations to guide dosing and prevent dangerous highs and lows
• Type 2 Diabetes (largest) – A metabolic disorder involving insulin resistance, where CGM use helps patients and clinicians adjust medication, diet, and lifestyle based on glucose trends
• Gestational Diabetes – A temporary form of glucose intolerance diagnosed during pregnancy, monitored with CGM to protect maternal and fetal health until delivery
• Other Diabetes/Metabolic Monitoring – A category covering prediabetes, wellness, and non-diabetic metabolic tracking, where CGM is used to observe glycemic response outside formal diabetes diagnoses

• Prediabetes
• Non-Diabetic Wellness/Metabolic Monitoring
• Hospital/Critical Care Glucose Monitoring

Regional Analysis

North America held 44.0% of the market in 2025, the largest of the three regions disclosed. Access here is shaped less by procurement than by the label itself: FDA clearance of factory-calibrated sensors for patients as young as two removed prior prescription age restrictions, widening the pediatric population a sensor can legally be marketed to and expanding the addressable base beyond adult Type 1 and Type 2 patients.

Asia Pacific followed at 29.0%. Growth here runs through public procurement rather than product label: China’s volume-based procurement tendering sets the price and channel through which sensors reach the country’s very large diagnosed diabetic population, making national tender outcomes as consequential to regional revenue as any single product launch.

Europe held 21.0% of the market in 2025. The region’s constraint is structural rather than clinical: EU MDR recertification obligations fall on CGM manufacturers with devices already on the market, adding a compliance cost layer that has no equivalent in the North American clearance pathway and that weighs disproportionately on smaller device lines.

South America carries no disclosed share, but the region’s access gap is documented directly. A 2025 cohort study at a Brazilian public diabetes clinic found that none of 92 people with Type 1 diabetes had regular CGM access under the public system (SUS) or private insurance, relying instead on four to five daily fingerstick tests, a reminder that device penetration tracks reimbursement inclusion as much as clinical need.

Competitive Landscape

The Continuous Glucose Monitoring Devices Market is consolidated. Competition centers on clinical evidence supporting sensor accuracy claims, regulatory clearance status, reimbursement coverage and coding, and the consumable lock-in of a sensor-transmitter-reader ecosystem once a patient is established on a platform. Switching costs are real: a payer contract and a patient’s trained routine both attach to one manufacturer’s form factor, which favors incumbents with broad label coverage over new entrants competing on accuracy alone.

No single-figure share of the top players is disclosed, but the market is led by an established group of manufacturers: Dexcom, Abbott Laboratories, Medtronic, Senseonics Holdings, Roche Diabetes Care, Ascensia Diabetes Care, Ypsomed, GlucoTrack, Tandem Diabetes Care and Nemaura Medical. This group spans the US, Ireland, Switzerland and the UK, reflecting a competitive base concentrated among established medical device manufacturers rather than diffuse regional players, consistent with a market where regulatory clearance and payer contracts are the entry barrier.

Strategic Outlook

The clearest whitespace sits in non-insulin-intensive Type 2 and prediabetic monitoring, a population CGM has barely reached because coverage has historically tracked insulin therapy rather than glycemic risk. Manufacturers with broad indication labels stand to benefit most, provided payers keep extending coverage past insulin-treated patients toward the wider metabolic-risk population already visible in the indication mix.

Toward 2035, expect the sensor-transmitter-reader bundle to keep consolidating around single-manufacturer ecosystems, with real-time, alarm-enabled sensing displacing intermittently scanned formats as the default rather than the premium option.

Continuous Glucose Monitoring Devices Market Report Scope